Clinical and Basic Research on the Treatment of Polycystic Ovary Syndrome

Launched by JIANGXI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE · Oct 7, 2019

Keywords

ClinConnect Summary

No description provided

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • 1. Diagnosed as PCOS patients, the diagnostic criteria is: modify the Rotterdam criteria. All subjects must have: no ovulation, combined with polycystic ovarian or / and hyperandrogenism.
• • 2. Age: 20 to 40 years old, no maternity requirements.
• • 3. Willing to be treated according to the treatment plan specified in this study.
• Exclusion Criteria:
• • 1. Hyperprolactinemia: In the past year, patients with normal levels can be included.
• • 2. Menopausal FSH levels：FSH \> 15 mIU/mL. In the past year, patients with normal levels can be included.
• • 3. Patients with thyroid disease: TSH \< 0.2 mIU/mL or \>5.5 mIU/mL. In the past year, patients with normal levels can be included.
• • 4. Patients with poorly controlled type 2 diabetes:HbA1c\>7.0%, or patients receiving antidiabetic drugs.
• • 5. Patients currently diagnosed with severe anemia (HGB \<10 g/dL).
• • 6. Patients with a history of alcohol abuse: Alcohol is defined as drinking 14 times a week or more or binge drinking.
• • 7. Currently suspected Cushing's syndrome patients.
• • 8. Patients suspected of having adrenal or ovarian tumors secreting androgen.
• • 9. In patients with hypertension who are currently untreated or have poor blood pressure control, the interval between two blood pressure measurements is ≥ 60 min, systolic blood pressure ≥ 160 mm Hg or diastolic blood pressure ≥ 100 mm Hg.
• • 10. Patients currently diagnosed with metabolic syndrome
• • 11. Take hormonal drugs, Chinese medicine prescriptions and proprietary Chinese medicines in the last 3 months.
• • 12. There is a history of pregnancy in the last 6 weeks.
• • 13. Abortion or production history in the last 6 weeks.
• • 14. A history of breastfeeding in the last 6 months.
• • 15. Patients with a history of deep vein thrombosis, pulmonary embolism or cerebrovascular disease.
• • 16. Patients with severe primary diseases such as cardiovascular, liver, kidney and hematopoietic system, and mental patients
• • 17. Patients who are expected to discontinue treatment during the trial or who are unable to adhere to treatment for 3 months should be excluded.
• • 18. Reluctant to sign the informed consent form for this study.